Presentation is loading. Please wait.

Presentation is loading. Please wait.

Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable.

Published byClemence Morris Modified over 5 years ago

Similar presentations

Presentation on theme: "Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable."— Presentation transcript:

1 Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study  Zhuo Zhang, PhD, Hiroe Shiratsuchi, PhD, Nallasivam Palanisamy, PhD, Sunitha Nagrath, PhD, Nithya Ramnath, M.B.B.S.  Journal of Thoracic Oncology  Volume 12, Issue 2, Pages (February 2017) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Tumor status of the patient. (A) Computed tomography scan at initial diagnosis and when the patient was resistant to crizotinib. (B) EML4-ALK rearrangement is detected in the tumor biopsy specimen (indicated by the arrowheads) at the initial visit by fluorescence in situ hybridization (original magnification, ×1000). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Mutation analysis of expanded circulating tumor cells (CTCs). Expanded CTCs, during the three clinical visits, are positive for EML4-ALK rearrangement by fluorescence in situ hybridization (original magnification, ×1000). Arrows point toward the CTCs harboring EML4-ALK. DNA sequencing revealed a L1196M mutation in expanded CTCs when the patient developed resistance to crizotinib (on the second visit) and an absence of the mutation when brain metastasis occurred (on the third visit). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Half maximal inhibitory concentrations of cells treated with crizotinib and ceritinib. Expanded circulating tumor cells (CTCs) are compared with pure cancer-associated fibroblasts (CAFs), a resistant cell line (i.e., A549), and a sensitive cell line (i.e., H3122). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,

Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma  Qiushi Wang, Xin Yang, Yong He, Qiang Ma, Li Lin,
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,

Analysis of ERBB Ligand-Induced Resistance Mechanism to Crizotinib by Primary Culture of Lung Adenocarcinoma with EML4-ALK Fusion Gene  Madoka Kimura,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients  Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,
FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma  Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC  Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.
Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non– small-cell Lung Cancer Exhibiting Resistance to Ceritinib  Gouji Toyokawa,
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 

Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases  Jennifer M. Boland, MD, Jin.

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases  Jennifer M. Boland, MD, Jin.

Similar presentations

Ads by Google